Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care - SAKK 33/99

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages 303-309

  Passweg, Jakob R ^a   Giagounidis, Aristoteles A N ^a   Simcock, Mathew ^a   Aul, Carlo ^a   Dobbelstein, Christiane ^a   Stadler, Michael ^a   Ossenkoppele, Gert ^a   Hofmann, Wolf Karsten ^a   Schilling, Kristina ^a   Tichelli, André ^a   Ganser, Arnold ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LYMPHOCYTE ANTIBODY;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLEEDING; BLOOD TRANSFUSION; FEMALE; FEVER; HEMATOPOIESIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SERUM SICKNESS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS;

ADULT; AGED; ANTILYMPHOCYTE SERUM; CELL TRANSFORMATION, NEOPLASTIC; CROSS-OVER STUDIES; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SERVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79951996237     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.2686     Document Type: Article

References (36)

1. Nimer SD: Myelodysplastic syndromes. Blood 111:4841-4851, 2008
2. Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997 (Pubitemid 27132124)
3. Marcondes M, Deeg HJ: Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): When, how and for whom? Best Pract Res Clin Haematol 21:67-77, 2008 (Pubitemid 351377509)
4. Cutler CS, Lee SJ, Greenberg P, et al: A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104:579-585, 2004 (Pubitemid 38900045)
5. List A, Kurtin S, Roe DJ, et al: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352:549-557, 2005 (Pubitemid 40204668)
6. Silverman LR, McKenzie DR, Peterson BL, et al: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-3903, 2006 (Pubitemid 46630737)
7. Malcovati L: Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 31:S2-S6, 2007 (suppl 3)
8. Mufti GJ, Figes A, Hamblin TJ, et al: Immunological abnormalities in myelodysplastic syndromes: I. Serum immunoglobulins and autoantibodies. Br J Haematol 63:143-147, 1986 (Pubitemid 16113739)
9. Voulgarelis M, Giannouli S, Ritis K, et al: Myelodysplasia associated autoimmunity: Clinical and pathophysiologic concepts. Eur J Clin Invest 34:690-700, 2004 (Pubitemid 39423027)
10. Billström R, Johansson H, Johansson B, et al: Immune mediated complications in patients with myelodysplastic syndromes: Clinical and cytogenetic features. Eur J Haematol 55:42-48, 1995
11. Hamblin TJ: Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33:150-162, 1996
12. Melenhorst JJ, Eniafe R, Follmann D, et al: Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 119:97-105, 2002 (Pubitemid 35176503)
13. Barrett J, Sloand EM, Young N: Immunologic mechanisms and gene expression patterns in myelodysplastic syndromes, in Greenberg PL (ed): Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, United Kingdom, Cambridge University Press, 2006, pp 147-171
14. Sloand EM, Kim S, Fuhrer M, et al: Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 100:4427-4432, 2002 (Pubitemid 35429681)
15. Sloand EM, Mainwaring L, Fuhrer M, et al: Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106:841-851, 2005 (Pubitemid 41076423)
16. Kochenderfer JN, Kobayashi S, Wieder ED, et al: Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100:3639-3645, 2002 (Pubitemid 35303934)
17. Chamuleau ME, Westers TM, van Dreunen L, et al: Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome. Haematologica 94:496-506, 2009
18. Barrett AJ, Sloand E: Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 94:449-451, 2009
19. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al: Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102:1314-1322, 1998 (Pubitemid 28435218)
20. Tichelli A, Gratwohl A, Wuersch A, et al: Antilymphocyte globulin for myelodysplastic syndrome. Br J Haematol 68:139-140, 1988
21. Molldrem JJ, Caples M, Mavroudis D, et al: Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99:699-705, 1997 (Pubitemid 27519877)
22. Molldrem JJ, Leifer E, Bahceci E, et al: Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137:156-163, 2002 (Pubitemid 34827511)
23. Aivado M, Rong A, Stadler M, et al: Favourable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a 'non-clonal' pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68:210-216, 2002
24. Killick SB, Mufti G, Cavenagh JD, et al: A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 120:679-684, 2003
25. Yazji S, Giles FJ, Tsimberidou AM, et al: Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17:2101-2106, 2003 (Pubitemid 37428374)
26. Steensma DP, Dispenzieri A, Moore SB, et al: Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101:2156-2158, 2003 (Pubitemid 36302052)
27. Asano Y, Maeda M, Uchida N, et al: Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 80:634-638, 2001 (Pubitemid 33725587)
28. Miyata A, Yasuda Y, Fujii S, et al: Outcome of immunosuppressive therapy for myelodysplastic syndromes: Results of 12 cases from a single institution. Rinsho Ketsueki 43:911-917, 2002
29. Jonásova A, Neuwirtová R, Cermák J, et al: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100:304-309, 1998 (Pubitemid 28131061)
30. Stadler M, Germing U, Kliche KO, et al: A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18:460-465, 2004 (Pubitemid 38425859)
31. Broliden PA, Dahl IM, Hast R, et al: Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91:667-670, 2006 (Pubitemid 43799466)
32. Sloand EM, Wu CO, Greenberg P, et al: Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 26:2505-2511, 2008
33. Lim ZY, Killick S, Germing U, et al: Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia 21:1436-1441, 2007 (Pubitemid 46965284)
34. Saunthararajah Y, Nakamura R, Nam JM, et al: HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100:1570-1574, 2002 (Pubitemid 34925129)
35. Cheson BD, Greenberg PL, Bennett JM, et al: Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425, 2006 (Pubitemid 44061337)
36. Park S, Grabar S, Kelaidi C, et al: Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: The GFM experience. Blood 111:574-582, 2008